CAR T cells in solid tumors: challenges and opportunities.

Area of Science:

• Immunotherapy
• Oncology
• Cellular Engineering

Background:

• Chimeric antigen receptor (CAR) T cells are engineered T cells for targeted cancer therapy, demonstrating success in hematologic malignancies.
• CARs comprise an scFv, transmembrane domain, and intracellular ITAMs for T cell activation.
• Current CAR T cell therapy efficacy is limited in solid tumors due to challenges in tumor recognition, trafficking, and survival.

Purpose of the Study:

• To review CAR T cell signaling and efficacy in solid tumors.
• To identify key barriers hindering CAR T cell therapy in solid tumors.
• To discuss novel therapeutic strategies for improving CAR T cell outcomes in non-hematologic malignancies.

Main Methods:

• Review of existing literature on CAR T cell therapy in solid tumors.
• Analysis of CAR T cell signaling pathways and mechanisms of action.
• Evaluation of challenges including tumor microenvironment (TME) and T cell exhaustion.

Main Results:

• CAR T cells function as 'living drugs' with potent anti-tumor effects.
• The immunosuppressive TME significantly impairs CAR T cell function.
• Combination therapies, including checkpoint blockade, show promise in reducing T cell exhaustion.

Conclusions:

• Overcoming CAR T cell dysfunction is critical for solid tumor treatment.
• Novel therapeutic approaches are needed to enhance CAR T cell proliferation and tumor cell lysis.
• Advancements in CAR T cell therapy hold promise for treating non-hematologic malignancies.